Scholarlink

Background <p>Severe carcinoid heart disease (CaHD) may require bioprosthetic valve (BPV) replacement. Lutetium-177 (Lu-177) DOTATATE is increasingly utilized in patients with neuroendocrine tumors (NETs); however, its effect on BPVs remains unknown.</p> Methods <p>A retrospective review of patients with CaHD who underwent BPV replacement at three tertiary centers in the United States was conducted. Patients were stratified by Lu-177 DOTATATE therapy with a propensity-matched non-exposed cohort. BPV degeneration and mortality were compared.</p> Results <p>Of 183 patients with CaHD and BPV replacement (median age 62.9 years, 50.8% male), 27 received Lu-177 DOTATATE (16 postoperatively, 11 preoperatively). BPVs treated with Lu-177 DOTATATE postoperatively demonstrated increased BPV degeneration (HR 4.42, 95%CI 3.29–5.93, <i>p</i> &lt; 0.001). BPVs in patients preoperatively exposed to Lu-177 DOTATATE showed no difference in degeneration. There was no difference in mortality in those treated or not treated with Lu-177 DOTATATE.</p> Conclusions <p>Our findings suggest an association between postoperative Lu-177 DOTATATE and increased BPV degeneration in CaHD patients. Where feasible, therapy prior to valve replacement should be considered.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluating the impact of Lutetium-177 therapy on bioprosthetic heart valves in carcinoid heart disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月20日

查看全文
  • Isabel G. Scalia,
  • Fatmaelzahraa E. Abdelfattah,
  • Juan M. Farina,
  • Omar H. Ibrahim,
  • Kamal Awad,
  • Juan A. Crestanello,
  • Hartzell V. Schaff,
  • Thorvardur R. Halfdanarson,
  • Jordan C. Ray,
  • Patricia A. Pellikka,
  • Heidi M. Connolly,
  • Reza Arsanjani,
  • Chadi Ayoub

摘要

Background

Severe carcinoid heart disease (CaHD) may require bioprosthetic valve (BPV) replacement. Lutetium-177 (Lu-177) DOTATATE is increasingly utilized in patients with neuroendocrine tumors (NETs); however, its effect on BPVs remains unknown.

Methods

A retrospective review of patients with CaHD who underwent BPV replacement at three tertiary centers in the United States was conducted. Patients were stratified by Lu-177 DOTATATE therapy with a propensity-matched non-exposed cohort. BPV degeneration and mortality were compared.

Results

Of 183 patients with CaHD and BPV replacement (median age 62.9 years, 50.8% male), 27 received Lu-177 DOTATATE (16 postoperatively, 11 preoperatively). BPVs treated with Lu-177 DOTATATE postoperatively demonstrated increased BPV degeneration (HR 4.42, 95%CI 3.29–5.93, p < 0.001). BPVs in patients preoperatively exposed to Lu-177 DOTATATE showed no difference in degeneration. There was no difference in mortality in those treated or not treated with Lu-177 DOTATATE.

Conclusions

Our findings suggest an association between postoperative Lu-177 DOTATATE and increased BPV degeneration in CaHD patients. Where feasible, therapy prior to valve replacement should be considered.

Graphical Abstract